Clinical Trials Logo
  1. Home
  2. Pneumococcal Vaccines
  3. NCT06151288

Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults

Pneumococcal Vaccines Clinical Trial

Official title:
A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Active-Controlled, Parallel-Group, Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Healthy Adults Aged 50 Years and Older

Clinical Trial Summary

The objective of the study is to evaluate the safety, tolerability and immunogenicity of a single injection of VAX-31 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 50 to 64 years of age in Stage 1. Stage 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-31 at 3 dose levels compared to PCV20 in adults aged 50 years and older.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06151288
Study type Interventional
Source Vaxcyte, Inc.
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date November 8, 2023
Completion date September 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT01953510 - Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam Phase 2/Phase 3
Completed NCT05540028 - Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine Phase 1
Recruiting NCT05298800 - Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 Phase 4
Active, not recruiting NCT06077656 - Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine Phase 2
Recruiting NCT06000397 - Reminder Emails to Improve Pneumococcal Vaccine Completion at 12 Months of Age N/A
Completed NCT00574548 - Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS Phase 3
Not yet recruiting NCT06271681 - Evaluation of PCV15 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans Phase 4
Active, not recruiting NCT05844423 - Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants Phase 2
Completed NCT00824655 - Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children Phase 3
Completed NCT01646398 - A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older Phase 3
Completed NCT00464945 - Wyeth Study To Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants Phase 3
Completed NCT03893448 - Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) Phase 3
Completed NCT05297578 - Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults Phase 2
Completed NCT01964716 - 13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants. Phase 3
Completed NCT05266456 - Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults Phase 1/Phase 2
Completed NCT01537185 - Phase I Safety Trial of Streptococcus Pneumoniae Whole Cell Vaccine (SPWCV) + Alum in Healthy Adults Phase 1
Recruiting NCT00999739 - Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected Adults Phase 3
Not yet recruiting NCT05721456 - Evaluation of the Non-Inferiority of a 12-Valent Pneumococcal Conjugate Vaccine in Healthy Children in Brazil. Phase 3
Active, not recruiting NCT02012309 - Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses N/A
Completed NCT01392378 - Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13® Phase 4